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Objective. The aim of the present study was to correlate new periprocedural diﬀusion-weighted imaging (DWI) lesions during
stenting of supra-aortal arteries with the level of platelet inhibition using point-of-care analysis. Background. Cardiological studies
have shown that patients undergoing coronary PTA have a signiﬁcantly elevated risk of severe thrombotic complications if patients
show insuﬃcient inhibition of platelet function. Methods. From August 2008 to June 2009, 44 patients with an indication of supra-
aortal angioplasty and/or stenting were prospectively enrolled. Platelet reactivity was tested using a Multiplate device (Dynabyte).
These patients underwent MRI before and after the intervention to determine the prevalence of new DWI lesions. The primary
endpoint was the prevalence of DWI lesions; the secondary endpoint was clinical status until discharge from hospital. Results.
There was no signiﬁcant relationship between the primary endpoint and the degree of platelet function. Patients with high platelet
reactivity showed the same amount of periprocedural complications as patients with suﬃcient inhibition of platelets. Conclusions.
Clopidogrel did not have a protective eﬀect on periprocedural complications, nor did it decrease the number of silent DWI lesions
after the procedure. The predescribed strong relationship between high platelet reactivity and early post-procedural adverse events
was not observed in our cohort.
1.Introduction
Several studies have shown that patients with a low response
ratetoclopidogrel,measuredbyinvitrofunctionofplatelets,
have a signiﬁcantly increased risk of early stent thrombo-
sis after percutaneous transluminal coronary angioplasty
(PTCA) and stenting compared to patients with suﬃcient
inhibition of platelets [1–7]. The aim of this prospective trial
wastoexamineifthereisarelationshipbetweentheresponse
to clopidogrel and clinical adverse events after supra-aortal
percutaneous transluminal angioplasty (PTA) and stenting
as well as the amount of newly occurred silent diﬀusion-
weighted imaging (DWI) lesions.
The DWI lesion load is a known indicator of microem-
bolic events after neurovascular interventions [8, 9], so it
was the primary target variable. Platelet reactivity was tested
using a Multiplate analyzer from Dynabyte GmbH (Munich,
Germany). This device is based on multiple electrode
aggregometry.Onestudyshowedacorrelationbetweenalow
responsetoclopidogrelmeasuredbyMultiplateandclinically
adverse events after supraaortal stenting [2]. In the present
study, we additionally used MRI to correlate the DWI lesion
load with the platelet reactivity.
2. Patients andMethods
From August 2008 to June 2009, 44 patients with stenoses
of supraaortal vessels and indication for treatment were
prospectively enrolled (Table 1). Inclusion criteria were2 Stroke Research and Treatment
Table 1: Vessels that underwent intervention.
Total 44
Symptomatic 33 (=75%)
Stroke 26 (=59%)
TIA 7 (=16%)
Asymptomatic 11 (=25%)
Location
Carotid artery
Extracranial stent 35
Intracranial stent 1
Extracranial PTA 1
Vertebral artery
Extracranial stent 4
Intracranial stent 1
Basilar artery stent 1
Middle cerebral artery PTA 1
symptomatic stenoses of at least 50% or asymptomatic
high-grade (>80%) carotid artery stenoses. Patients with
contraindications for MRI were excluded. 42 patients under-
went PTA and stenting, and 2 patients received PTA only.
43 patients were treated with ASS 100mg and clopidogrel
75mg daily at least three days before the intervention, one
received a loading dose of 300mg clopidogrel and 500mg
ASS just before the intervention because an urgent treatment
was necessary. Prior to the procedure, blood samples were
taken directly from the arterial sheath with sample tubes
equipped for the Multiplate system, which contain hirudine
as anticoagulant. The test results were available after the
procedure. Afterwards patients were monitored at the Stroke
Unitofourinstitution.Theyunderwentclinicalexamination
to assess if new neurological deﬁcits had occurred.
2.1. MRI. MRI was undertaken on a 1.5-T Siemens Sonata
scanner (Siemens AG, Erlangen, Germany). DWI were ac-
quiredusingourstandardprotocol.Thiscomprisedisotropic
echoplanar sequences with a repetition time of 4,100ms;
echo time of 104ms; ﬁeld of view of 210mm; a matrix of
128 × 128; number of excitations = 2; slice thickness of
6mm; with b values of 0, 500, and 1000s/mm2.I m a g e sw e r e
compared with preprocedural images by two experienced
neuroradiologists unaware of the clinical outcome.
2.2. Blood Analyses. Blood samples were immediately trans-
ferred to the Department of Hemostaseology of our insti-
tution. Testing was undertaken in <3h on the Multiplate
analyzer [2, 5]. This device is based on impedance aggre-
gometry; in particular, adenosine diphosphates- (ADP-) in-
duced aggregometry is suitable for detecting the response to
clopidogrel.
Three hundred microliters of the patients’ whole blood
samples,anticoagulatedbyhirudine,werepipettedintoatest
cell containing 2 × 2 electrodes, as well as 6.4µmol/L ADP.
Aggregation of platelets continuously increased the electri-
cal resistance between the electrodes over the test period of
6 minutes per sample. This value was shown as aggregation
units (AU) over time in a graph. The area under the curve,
given in arbitrary units (U) represented the platelet aggrega-
tion and provided the test results.
The test cell contained two pairs of electrodes, so the re-
sults were already the mean value of two simultaneous meas-
urements. As suggested in [10], the patients’ platelet reac-
tivity has been deﬁned as “high on treatment” if the results
exceeded 468 AU∗min in response to ADP.
2.3. Statistical Analysis. Acquired data were analyzed using
SPSS software (SPSS, Chicago, IL, USA).
The patients’ platelet aggregation values, which were giv-
en in arbitrary units (U), were correlated with the amount
of new DWI lesions by using a nonparametric test for inde-
pendent values (Mann-Whitney test).
Additionally, a 2 by 2 table consisting of platelet activity
status (according to the consensus [10]) and DWI lesions
yes/no has been created and analyzed with a chi-square test.
3. Results
The values from the ADP-induced aggregometry ranged
from 3 units to 88 AU (mean, 34.6 AU; standard deviation
(SD), 20.24) (Figure 1). The distribution of ADP test values
was similar in patients with and without new DWI lesions
(Figure 3).
In these cases in which aggregation exceeded 468
AU∗min, platelet reactivity was deﬁned as “high.” This re-
sulted in 11 patients with high platelet reactivity out of 44
enrolled patients (25%).
After the procedure 16 out of 44 patients (36%) showed
new DWI lesions. These were silent DWI lesions in 13
cases. Two patients suﬀered a periprocedural stroke, and one
patient suﬀered a reperfusion trauma. The ADP-test values
of these cases were 18, 24, and 64 units. That is, one of the
two patients that suﬀered a periprocedural stroke showed
high platelet reactivity whereas the other case as well as the
patient with reperfusion trauma had suﬃcient suppression
of platelets.
Of the 11 patients with insuﬃcient platelet suppression
who underwent MRI, 4 (36%) showed new DWI lesions
(Figure 2). Of 33 patients with suﬃcient platelet inhibition,
11 (36%) had DWI lesions after the procedure (Figure 2). A
statistically signiﬁcant relationship between ADP-test values
respectively platelet reactivity and MRI evidence of new
DWI lesions (P = 0.893 from the Mann-Whitney test, P =
0.635 from the chi square test) or between outcome was not
observed. However, three clinically aﬀected patients is not
suﬃcient for a statistical conclusion.
4. Discussion
Clopidogrel resistance is dependent upon the genetic back-
groundofthepatient.CytochromeCYP2C19isanimportant
enzyme that metabolizes clopidogrel. Individuals with an
impaired allele (which seems to represent about one-third
of the population) show ≤30% less active metabolism ofStroke Research and Treatment 3
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Figure 1: Distribution of ADP values from the study population,
includingthreepatientsthatreceivedaloadingdose,andthosefrom
the reference group (“Reference” in this ﬁgure means a combined
reference range of healthy male and female blood donors).
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Figure 2: Shows the number of patients with (blue) and without
(red) DWI lesions among responders and non-responders.
clopidogrel in plasma. Furthermore, carriers of such an allele
showed an elevated risk of death by cardiovascular causes,
infarction, or stroke of 53% in the TRITON-TIMI 38 trial
(Trial to Assess Improvement in Therapeutic Outcomes by
Optimizing Platelet Inhibition with Prasugrel-Thrombolysis
in Myocardial Infarction) [11].
Studies focusing on the relationship between an inade-
quate response to clopidogrel and adverse events in cardio-
vascular or neurovascular interventions have shown a signi-
ﬁcant (or at least a considerable) connection [1–7, 11]. Most
of these studies concerned cardiovascular interventions.
Because of the diﬀerences in supra-aortal interventions with
respect to stent types, vessel sizes, and ﬂow characteristics,
the results of these studies should not be readily transferred
to other vessel territories. Furthermore, a common compli-
cation such as in-stent thrombosis shortly after PTCA is ex-
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Figure 3: Boxplots showing the distribution of ADP values for
patients with (right) and without DWI lesions (left) after the pro-
cedure.
tremelyrareinsupra-aortalstenting,thereforethetargetvar-
iables in both issues must be diﬀerent. M¨ uller-Schunk et al.
[2] were the ﬁrst to analyse the correlation between clopido-
grel resistance and procedural complications in supra-aortal
stenting. They found a signiﬁcant relationship between non-
response to clopidogrel and the clinical outcome.
In supra-aortal stenting, attention must be focused on
periprocedural strokes or the more frequently appearing
cerebral DWI lesions (which are usually clinically unremark-
able). These DWI lesions could help in the highly sensitive
detection of microembolic events.
If we compare a subgroup of our study population who
receivedunprotectedcarotidarterystenting(CAS,n=35),11
patients (31%) showed post-procedural DWI lesions. In the
literature, the percentage of DWI lesions after unprotected
CAS varies from 22% to 67% [8, 9, 12].
In contrast to previous studies, a relationship between
low response to clopidogrel and thromboembolic events was
not observed. These thromboembolic events are represented
by DWI lesions or peri- and post-procedural ischemic
strokes.
Of the 16 patients who showed MRI evidence of new
DWI lesions, three had clinically noticeable symptoms (as
mentioned above). Studies that rely only on the patients’
clinical outcomes will only detect small part of the adverse
events.
If patients undergo carotid stenting or vertebral stenting
with high platelet reactivity without negative consequences,
the need for screening of clopidogrel non-responders before
supra-aortal stenting must be questioned. Further studies
should show if low response to clopidogrel leads to a higher
rate of stent restenosis.
The non-response to clopidogrel has been investigated
in various studies. The deﬁnition of “non-response” in
the literature is inconsistent, making interstudy comparison
diﬃcult. The eﬀect of clopidogrel responsiveness in a patient
population forms a Gaussian distribution, so De Miguel [13]
suggested measurementof the degree of platelet inhibition as4 Stroke Research and Treatment
anominalvariableinsteadofdividing patientsintogroupsof
responders or non-responders. In [10], Bonello et al. suggest
to focus on the absolute level of platelet reactivity instead of
clopidogrel responsiveness. They present cut-oﬀ points for
several platelet aggregation analyzers which help to stratify
thromboembolic risks.
There are several possible alternatives for clopidogrel
low-responders undergoing coronary interventions, such
as increasing the loading dose from 300mg to 600mg,
which leads to a higher and stronger ADP-induced platelet
inhibition [14]. Another possibility is to try diﬀerent agents
such as prasugrel and ticagrelor. The latter recently showed
the characteristic of signiﬁcantly aﬀecting platelet inhibition
in clopidogrel non-responders in the RESPOND study [15].
5. Study Limitations
This study tries to correlate patients’ platelet aggregation
with the amount of new dwi lesions which is a common
indicator for the safety of neurovascular interventions. The
results diﬀer from preceding studies regarding the relation to
adverse events. However, 44 patients may not be enough to
evaluate a statistical relation. Especially the amount of three
clinically aﬀected patients is not enough for a conclusion.
Further studies with more participants are needed for
veriﬁcation.
6. Conclusion
Incontrasttotheprecedingstudies,wefoundnorelationship
between the patients’ response to clopidogrel and adverse
eventsrepresentedbymicroembolism,detectedbymriimag-
ing. So the need for point-of-care testing of platelet function
prior to angioplasty and stenting of supraaortal arteries must
be questioned.
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